Denali Advisors LLC Buys New Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Denali Advisors LLC acquired a new stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,600 shares of the company’s stock, valued at approximately $172,000. Denali Advisors LLC owned about 0.06% of Werewolf Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Financial Perspectives Inc raised its stake in shares of Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after buying an additional 3,000 shares in the last quarter. Certuity LLC purchased a new position in Werewolf Therapeutics in the 4th quarter valued at approximately $39,000. Lighthouse Investment Partners LLC purchased a new position in Werewolf Therapeutics in the 4th quarter valued at approximately $87,000. Finally, PFM Health Sciences LP increased its stake in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after purchasing an additional 909,895 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Trading Up 3.9 %

Shares of HOWL stock traded up $0.08 during mid-day trading on Wednesday, hitting $2.14. 170,541 shares of the company’s stock were exchanged, compared to its average volume of 274,031. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $8.19. The stock has a 50-day simple moving average of $4.35 and a two-hundred day simple moving average of $5.11. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24. The stock has a market cap of $92.99 million, a price-to-earnings ratio of -1.89 and a beta of 0.47.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, May 3rd. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $9.00 target price on shares of Werewolf Therapeutics in a report on Monday, June 3rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $12.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, June 26th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.